Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder.

J Child Adolesc Psychopharmacol · 2023 · PMC10733774 · PMID 38055198

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For all secondary endpoints in the double-blind period, the ESC group showed a trend toward improvement compared with the placebo group at week 48, and four of six endpoints, including change from start of the double-blind period in CDRS-R total score, were statistically significantly different between the two groups.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.